User profiles for Erica Bäckström

Erica Bäckström

RIA iMed AstraZeneca
Verified email at vigo.se
Cited by 379

Drug metabolism in the lungs: opportunities for optimising inhaled medicines

Z Enlo-Scott, E Bäckström, I Mudway… - Expert Opinion on Drug …, 2021 - Taylor & Francis
Introduction The lungs possess many xenobiotic metabolizing enzymes which influence the
pharmacokinetics and safety of inhaled medicines. Anticipating metabolism in the lungs …

Mechanisms of inflammatory lung injury in the neonate: lessons from a transgenic mouse model of bronchopulmonary dysplasia

K Bry, A Hogmalm, E Bäckström - Seminars in perinatology, 2010 - Elsevier
The role of inflammation in the pathogenesis of bronchopulmonary dysplasia (BPD) is not
well understood. By using a transgenic mouse expressing the inflammatory cytokine …

Development of a novel lung slice methodology for profiling of inhaled compounds

E Bäckström, A Lundqvist, E Boger, P Svanberg… - Journal of …, 2016 - Elsevier
The challenge of defining the concentration of unbound drug at the lung target site after
inhalation limits the possibility to optimize target exposure by compound design. In this study, a …

[HTML][HTML] Developmental stage is a major determinant of lung injury in a murine model of bronchopulmonary dysplasia

E Bäckström, A Hogmalm, U Lappalainen, K Bry - Pediatric research, 2011 - nature.com
Bronchopulmonary dysplasia (BPD) is a common inflammatory lung disease in premature
infants. To study the hypothesis that the sensitivity of the lung to inflammatory injury depends …

Lung retention by lysosomal trapping of inhaled drugs can be predicted in vitro with lung slices

E Bäckström, E Boger, A Lundqvist… - Journal of …, 2016 - Elsevier
Modulating and optimizing the local pharmacokinetics of inhaled drugs by chemical design
or formulation is challenged by the lack of predictive in vitro systems and in vivo techniques …

Uncovering the regional localization of inhaled salmeterol retention in the lung

E Bäckström, G Hamm, A Nilsson, BM Fihn… - Drug Delivery, 2018 - Taylor & Francis
Abstract Treatment of respiratory disease with a drug delivered via inhalation is generally
held as being beneficial as it provides direct access to the lung target site with a minimum …

Revealing the regional localization and differential lung retention of inhaled compounds by mass spectrometry imaging

GR Hamm, E Bäckström, M Brülls… - Journal of Aerosol …, 2020 - liebertpub.com
Background: For the treatment of respiratory disease, inhaled drug delivery aims to provide
direct access to pharmacological target sites while minimizing systemic exposure. Despite …

[HTML][HTML] Pulmonary metabolism of substrates for key drug-metabolizing enzymes by human alveolar type II cells, human and rat lung microsomes, and the isolated …

K Rubin, P Ewing, E Bäckström, A Abrahamsson… - Pharmaceutics, 2020 - mdpi.com
Significant pulmonary metabolism of inhaled drugs could have drug safety implications or
influence pharmacological effectiveness. To study this in vitro, lung microsomes or S9 are …

Role of CXC Chemokine Receptor–2 in a Murine Model of Bronchopulmonary Dysplasia

A Hogmalm, E Bäckström, M Bry… - American Journal of …, 2012 - atsjournals.org
The contribution of neutrophils and CXC chemokines to the pathogenesis of bronchopulmonary
dysplasia is not well defined. The transgenic expression of IL-1β in the pulmonary …

Tissue pharmacokinetics of antisense oligonucleotides

E Bäckström, A Bonetti, P Johnsson, S Öhlin… - … Therapy-Nucleic Acids, 2024 - cell.com
Pharmacokinetics of antisense oligonucleotides (ASO) is characterized by rapid distribution
from plasma to tissue and slow terminal plasma elimination driven by re-distribution from …